On November 17, INSILICO fell 4.11% in Regular Trading, trading at HK$34.56, with turnover of HK$16.59 million.
The clearest catalyst in publicly available information was continued weakness across the Life Sciences Tools & Services sector, which appeared to outweigh the near-term support from the company’s latest share repurchase.
Company disclosures show INSILICO repurchased 262,000 shares on November 16 for about HK$9.22 million at HK$34.56 to HK$35.50 per share, while issuing 46,444 new shares the same day following option exercises under its pre-IPO equity incentive plan. Earlier, the company also announced a strategic AI drug discovery partnership with Luoxin Pharmaceuticals focused on digestive diseases, metabolic disorders and other chronic non-oncology indications. Even so, sector peers were broadly weak, including GENSCRIPT B-1K falling 5.97%, XTALPI falling 1.99% and WUXI XDC falling 1.91%, indicating industry pressure remained the more direct driver of the move.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments